Results
13
Gain exposure to companies in the healthcare sector with a strong future outlook and robust financials.
13 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
ABT | US$101.26 | -1.1% | 9.6% | US$195.6b | US$111.79 | PE35.3x | E11.7% | 2.0% | ||
SYK | US$321.20 | -1.9% | 23.3% | US$137.3b | US$332.19 | PE39.8x | E10.8% | 0.9% | ||
BSXC | US$75.00 | 0% | 49.1% | US$122.7b | US$78.52 | PE67.1x | E20.9% | n/a | ||
ABC | US$201.45 | -1.4% | 17.1% | US$44.1b | US$232.80 | PE23.7x | E11.3% | 0.9% | ||
IDXX | US$462.80 | 1.6% | 11.1% | US$42.1b | US$494.04 | PE49.8x | E10.3% | n/a | ||
RMD | US$219.80 | 0.6% | 55.1% | US$35.1b | US$199.58 | PE34.4x | E11.4% | 0.9% | ||
PHIA | €29.01 | 5.5% | 56.3% | €27.5b | €27.36 | PS1.5x | E58.8% | n/a | ||
DXCM | US$60.83 | -4.4% | -32.4% | US$27.0b | US$86.90 | PE40.4x | E16.5% | n/a | ||
FRE | €33.57 | 1.3% | 13.9% | €18.9b | €39.37 | PE26.2x | E23.7% | n/a | ||
FME | €37.95 | 4.0% | -7.1% | €11.2b | €38.53 | PE21.2x | E21.9% | 3.1% | ||
HSIC | US$65.78 | 2.2% | -6.2% | US$9.3b | US$65.83 | PE26.4x | E24.2% | n/a | ||
DEMA | DKK 35.80 | -0.3% | -8.8% | DKK 58.0b | DKK 40.46 | PE22.9x | E12.5% | n/a | ||
XRAY | US$24.47 | 3.3% | -25.1% | US$5.5b | US$28.11 | PS1.4x | E48.4% | 2.4% |